Cytokinetics Inc’s recently made public that its EVP Research & Development Malik Fady Ibraham unloaded Company’s shares for reported $0.15 million on Nov 18 ’25. In the deal valued at $66.45 per share,2,200 shares were sold. As a result of this transaction, Malik Fady Ibraham now holds 140,610 shares worth roughly $9.3 million.
Then, Kaye Edward M. MD sold 5,175 shares, generating $336,789 in total proceeds. Upon selling the shares at $65.08, the Director now owns 9,977 shares.
Before that, EDWARD KAYE bought 5,175 shares. Cytokinetics Inc shares valued at $321,885 were divested by the Director at a price of $62.20 per share.
A number of analysts have revised their coverage, including Barclays’s analysts, who began to cover the stock in late April with a ‘”an Overweight”‘ rating. Citigroup began covering CYTK with “Buy” recommendation on February 07, 2025. Stifel started covering the stock on January 22, 2025. It rated CYTK as “a Buy”.
Price Performance Review of CYTK
On Tuesday, Cytokinetics Inc [NASDAQ:CYTK] saw its stock fall -1.18% to $66.16. Over the last five days, the stock has lost -0.51%. Cytokinetics Inc shares have risen nearly 20.95% since the year began. Nevertheless, the stocks have risen 40.65% over the past one year. While a 52-week high of $67.98 was reached on 11/17/25, a 52-week low of $29.31 was recorded on 05/15/25.
Levels Of Support And Resistance For CYTK Stock
The 24-hour chart illustrates a support level at 65.51, which if violated will result in even more drops to 64.86. On the upside, there is a resistance level at 67.30. A further resistance level may holdings at 68.45.
How much short interest is there in Cytokinetics Inc?
A steep rise in short interest was recorded in Cytokinetics Inc stocks on 2025-10-31, dropping by -0.33 million shares to a total of 13.79 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 14.11 million shares. There was a decline of -2.36%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on November 08, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $80 price target.
